The Emyria Ltd (ASX: EMD) share price is see-sawing today despite the company winning a digital health monitoring grant. We take a look at the grant.
The post Why the Emyria (ASX:EMD) share price is seesawing today appeared first on The Motley Fool Australia. –
Shares in the healthcare technology and services company rose to an intraday high of 15 cents, before slightly pulling back. At the time of writing, the Emyria share price is up 3.5% to 14.5 cents.
Emyria, formerly known as Emerald Clinics, operates a network of specialist medical clinics and purpose-built, remote patient monitoring technologies. The company captures real-world clinical data and uses this to provide consultation letters, containing information on prescription, recommended dosage, and duration of cannabinoid-based medicines.
What did Emyria announce?
The Emyria share price is moving in both directions today as investors digest the company’s latest announcement.
In its release, the company advised that it was recently awarded a grant from Western Australia’s Future Health Research and Innovation Fund.
The grant aims to boost the state’s digital health infrastructure and capacity in dealing with future health concerns. In light of this, Emyria highlighted that it will take the leadership role in collaborating with major health services and universities. The company will seek to develop improved monitoring of mental health at-risk individuals and COVID-19 patients using its contactless remote monitoring platform, Openly.
The total grant is valued at $880,000. Emyria predicts it will receive around $320,000 to $400,000 over two years.
What is Openly?
Initially developed to remotely screen and manage COVID-19 patients, the platform moved into the digital health and wellness screening space. Using smart mobile devices, Openly collects real-world data by monitoring heart rate and heart rate variability. The information is then presented to a medical team who can act on any abnormal changes to vital signs.
Openly was registered as a class 1 medical device with the Australian Therapeutic Goods Administration (TGA) in September last year.
Emyria managing director Dr Michael Winlo commented on the successful grant:
It’s very pleasing to see our unique contactless remote monitoring platform – Openly – recognised through this competitive grant process. Emyria’s unique digital health technology and clinical team will be playing a major role in improving how we monitor the clinical and mental wellbeing of vulnerable populations in WA.
Openly – the core technology of this grant – will also support and monitor patients during our upcoming clinical trials. These pivotal studies will support the registration of our leading drug candidate EMD-003 – targeting unmet needs in psychological distress and the symptoms of anxiety, depression and stress.
About the Emyria share price
Looking at the historical Emyria share price chart, its shares are dead flat from this time last year.
The company’s shares have been on a rollercoaster ride, diving to as low as 3.8 cents in August then rising to reach a 52-week high of 16 cents just two weeks ago.
Based on the current share price, Emyria has a market capitalisation of $32 million.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
- What to expect from the Qantas (ASX:QAN) first half result
- 3 ASX dividend shares to own for retirement income
- Short sellers doubling down on these ASX stocks despite the GameStop saga
- Brokers name 3 ASX shares to buy right now
- Why the Genex (ASX:GNX) share price is up 5% today
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.